11 completed, 1 terminated. 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 11, Terminated 1 |
Follow casopitant: new trials by email Literature Review of casopitant trials Research Report on casopitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia | Phase 2 | Completed | GlaxoSmithKline | 68 | 2006-05-01 | 2015-04-16 |
| Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia | Phase 2 | Completed | GlaxoSmithKline | 342 | 2006-01-01 | 2015-04-15 |
| An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia GW679769 oral tablets, Placebo - Nonulcer Dyspepsia | Phase 2 | Completed | GlaxoSmithKline | 13 | 2006-01-01 | 2017-02-08 |
| Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia GW679769 - Sleep Initiation and Maintenance Disorders, Insomnia | Phase 2 | Completed | GlaxoSmithKline | 122 | 2006-01-01 | 2015-04-16 |
| Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients GW679769 - Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder | Phase 2 | Terminated | GlaxoSmithKline | 1 | 2006-01-01 | 2015-04-17 |
| A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder GW679769 oral tablets - Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder | Phase 2 | Completed | GlaxoSmithKline | 160 | 2005-12-01 | 2017-01-20 |
| Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD) GW679769 - Depressive Disorder, Major | Phase 2 | Completed | GlaxoSmithKline | 348 | 2005-06-01 | 2016-10-28 |
| Post-Operative Nausea And Vomiting Study In Female Patients GW679769 - Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative | Phase 2 | Completed | GlaxoSmithKline | 435 | 2005-02-01 | 2017-01-20 |
| Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy Aprepitant, Ondansetron, GW679769 - Nausea and Vomiting, Chemotherapy-Induced | Phase 2 | Completed | GlaxoSmithKline | 492 | 2005-02-01 | 2010-05-10 |
| Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy GW679769, Dexamethasone, Ondansetron Hydrochloride - Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting | Phase 2 | Completed | GlaxoSmithKline | 722 | 2004-12-01 | 2015-04-16 |
| Study Of GW679769 In Major Depressive Disorder GW679769 - Depressive Disorder, Major, Major Depressive Disorder (MDD) | Phase 2 | Completed | GlaxoSmithKline | 356 | 2004-10-01 | 2015-04-16 |
| A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia GW679769, Placebo - Sleep Initiation and Maintenance Disorders | Phase 2 | Completed | GlaxoSmithKline | 48 | 2004-07-30 | 2017-08-08 |
Sleep Initiation and Maintenance Disorders (4) · Vomiting (3) · Depressive Disorder, Major (2) · Nausea (2) · Urinary Bladder, Overactive (2) · Depression (1) · Mood Disorders (1) · Postoperative Nausea and Vomiting (1) · Spinal Cord Injuries (1) · Urinary Incontinence, Urge (1)
GlaxoSmithKline (12)
United States (9) · Canada (4) · Argentina (3) · Belgium (3) · Chile (3) · Germany (3) · Hong Kong (3) · Hungary (3) · Philippines (3) · Poland (3) · Slovakia (3) · Spain (3) · Austria (2) · Croatia (2) · Czechia (2)